Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myeloid, Acute 23Myelodysplastic Syndromes 14Leukemia, Myelomonocytic, Chronic 7Myeloproliferative Disorders 4Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Biphenotypic, Acute 2Anemia, Refractory, with Excess of Blasts 2Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Systemic Mastocytosis With an Associated Hematologic Neoplasm 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Neurofibrosarcoma 1Neuroendocrine Tumors 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Myeloid, Chronic-Phase 1Hodgkin Disease 1GATA2 Deficiency 1Cytopenia 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1BRCA1 Mutation 1

Interventions

Magnetic Resonance Spectroscopy 8Specimen Handling 7Biopsy 6X-Rays 5Phantoms, Imaging 5Temozolomide 4Nuclear Medicine Department, Hospital 4Nivolumab 4Carboplatin 4selpercatinib 3larotrectinib 3Topotecan 3Etoposide 3Cyclophosphamide 3Cisplatin 3Automobiles 3tazemetostat 2pembrolizumab 2erdafitinib 2entrectinib 2ensartinib 2cabozantinib 2Vincristine 2Surveys and Questionnaires 2Radiotherapy 2Radiosurgery 2Radiation 2Positron-Emission Tomography 2Paclitaxel 2ONC206 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Central Nervous System Neoplasms × decitabine and cedazuridine drug combination × 1 year × Clear all
NCT03922555 2026-04-16

ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

Massachusetts General Hospital

Phase 1 Recruiting
18 enrolled
CNS

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡